AL 4 1A1

Drug Profile

AL 4 1A1

Alternative Names: AL-4-1A1

Latest Information Update: 13 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allosterix Pharma
  • Class Small molecules
  • Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes; Rheumatoid arthritis

Highest Development Phases

  • Preclinical Rheumatoid arthritis
  • Research Dry eyes

Most Recent Events

  • 13 Jul 2016 Preclinical development is ongoing in Rheumatoid arthritis in Israel
  • 13 Jul 2016 AL 4 1A1 is available for licensing as of 13 Jul 2016.
  • 01 Mar 2016 Early research in Dry eyes in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top